GlaxoSmithKline is in line for an exit as CureVac files for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
CureVac, a Germany-based messenger RNA (mRNA) drug developer backed by pharmaceutical firm GlaxoSmithKline (GSK), on Friday filed for an initial public offering on the Nasdaq Global Market with a placeholder target of $100m.
The company has not yet set any terms for the proposed offering.
Spun out of Eberhard Karls University of Tübingen in 2000, CureVac is working on treatments that exploit mRNA to create immunotherapies aimed at diseases including cancer, as well as vaccines for infectious diseases such…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
